Xeris Pharmaceuticals Shares Extend Rally to Fresh Peak

Xeris Biopharma shares surged to unprecedented heights last week, establishing a new annual peak at $9.21 during Friday’s trading session. The company’s equity has demonstrated remarkable momentum, climbing 15.27% over a fortnight and accumulating gains exceeding 185% since the beginning of the calendar year, positioning it among the pharmaceutical sector’s top performers.

Financial Performance Exceeds Projections

The driving force behind this substantial appreciation becomes evident when examining the company’s most recent quarterly report. Xeris posted second-quarter 2025 revenue of $71.5 million, representing a substantial 49% year-over-year increase that comfortably surpassed market expectations. The standout performance came from the company’s flagship product Recorlev, which experienced explosive growth with net revenues skyrocketing 136% to reach $31.4 million.

Key financial highlights include:
* Revenue expansion: 49% quarterly growth for Q2 2025
* Recorlev performance: 136% revenue surge
* Earnings per share: -$0.01 compared to anticipated -$0.03
* Annual guidance: Revised upward to $280-290 million

Market participants are now looking ahead to November 6, when Xeris will disclose whether this positive trajectory continued into the third quarter.

Should investors sell immediately? Or is it worth buying Xeris Pharmaceuticals?

Analyst Sentiment Reinforces Bullish Outlook

The investment firm H.C. Wainwright reaffirmed its positive stance on Friday, maintaining a “buy” recommendation alongside a $10.00 price target. Among market researchers covering the company, the consensus average price projection stands at $7.08, with the most optimistic assessments reaching the $10.00 threshold.

Intellectual Property Strengthens Market Position

A significant development emerged in late August when the United States Patent Office granted additional protection for Recorlev, securing exclusive rights through March 2040. This represents the fourth patent listed in the FDA’s Orange Book for the medication, underscoring its long-term commercial potential within an underserved therapeutic area.

From a technical perspective, the equity’s chart configuration indicates a clear upward trend following its breakthrough to new annual highs. The critical consideration for investors now centers on whether Xeris can surpass the psychological $10.00 barrier or if the upcoming earnings release might trigger a consolidation phase.